Understand the source comparison
Peptide Industry Growth 2026 Market Trends: Segment Comparison
GLP-1 Receptor Agonists $21.3 billion 12.8% Obesity prevalence, diabetes management, cardiovascular risk reduction Approved (semaglutide, tirzepatide, liraglutide) Dominant segment. Supply constraints persist through 2027 despite capacity expansions Oncology P
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- GLP-1 Receptor Agonists
- $21.3 billion
- 12.8%
- Obesity prevalence, diabetes management, cardiovascular risk reduction
- Approved (semaglutide, tirzepatide, liraglutide)
- Dominant segment. Supply constraints persist through 2027 despite capacity expansions
- Oncology Peptides
- $6.8 billion
- 9.4%
- Targeted tumour receptor agonists, peptide-drug conjugates
- Mixed (27 in Phase II/III trials)
- High clinical failure rate (38%) but blockbuster potential for successful candidates
- Antimicrobial Peptides
- $1.2 billion
- 14.2%
- Antibiotic resistance crisis, hospital-acquired infections
- Early-stage (11 Phase I/II trials active)
- Regulatory pathway unclear. FDA treating as novel class requiring extensive safety data
- Neurodegenerative Peptides
- $890 million
- 7.9%
- Alzheimer's, Parkinson's, ALS therapeutic gaps
- Investigational (4 Phase III trials)
- Long development timelines. Most candidates target symptom management, not disease modification
- Metabolic Peptides (Non-GLP-1)
- $3.4 billion
- 10.1%
- NASH, lipid disorders, insulin sensitisation
- Approved and investigational
- Crowded pipeline. Differentiation requires head-to-head efficacy vs existing therapies